Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company ...

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Unicycive Therapeutics’ New Drug ...

Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of ...

Unicycive, which was seeking approval of oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, said the FDA issued a so-called complete response letter ...

The FDA has awarded the fast-track designation for the CKD indication based on that result, as well as the promise of an ongoing trial – EMPA-KIDNEY – which is looking at kidney disease ...

Unicycive had submitted the New Drug Application for OLC to treat hyperphosphatemia in patients with chronic kidney disease on dialysis. The company emphasized that the FDA has not highlighted any ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the. On June 4, the company published pre-specified analyses for its ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced the successful closing of its $18 million Series B financing. The round was led by ...